ArticleEuropean journal of medical research2025
Construction of a survival prognosis model for epithelial-mesenchymal transition-related genes in gastric cancer.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundGastric cancer (GC) is a prevalent malignancy with high mortality rate. The process of Epithelial-mesenchymal transition (EMT) significantly contributes to its metastasis and resistance to therapy. This research is designed to develop a survival prediction model for EMT-related genes in GC.
methodsThis study used GC data from public databases and screened core module genes via weighted gene co-expression network analysis (WGCNA). Subsequently, we combined univariate Cox regression and least absolute shrinkage and selection operator (LASSO) regression to identify key feature genes and establish a prognostic model for GC patients. The survival package was used for survival analysis, and the pROC package was employed to generate receiver operating characteristic (ROC) curves for evaluating model performance. The CIBERSORT and ESTIMATE algorithms were applied to assess immune cell infiltration in patients with different risk levels. Gene set enrichment analysis (GSEA) was conducted for pathway enrichment analysis. Finally, in vitro cell experiments were performed to verify the expression levels and potential biological functions of the key genes.
resultsWe obtained three key genes, NPR3, OLFML2B and GREB1, and established a prognostic RiskScore model consisting of these three key genes, and the area under ROC curve (AUC) > 0.6 confirmed the predictive efficacy of this model. GSEA confirmed that the tumor progression pathways, such as EMT, angiogenesis, and so on, were notably activated in high-risk group. Moreover, patients in high-risk group exhibited a stronger tendency to immune escape and were significantly less sensitive to Afatinib, Gefitinib, and Lapatinib. Finally, in vitro tests displayed that NPR3 knockdown markedly decreased the viability, migration and invasion of GC cells.
conclusionOur study provides a prognostic assessment tool for GC based on EMT-related genes and offers novel insights into understanding the roles of EMT in GC progression and treatment resistance. These findings may aid in the development of precision therapy strategies for GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.